292 related articles for article (PubMed ID: 22646257)
1. Treatment options for unresectable neuroendocrine liver metastases.
John BJ; Davidson BR
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):357-69. PubMed ID: 22646257
[TBL] [Abstract][Full Text] [Related]
2. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
3. Management of advanced neuroendocrine tumors with hepatic metastasis.
Khasraw M; Gill A; Harrington T; Pavlakis N; Modlin I
J Clin Gastroenterol; 2009 Oct; 43(9):838-47. PubMed ID: 19654558
[TBL] [Abstract][Full Text] [Related]
4. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
Nakakura EK; Venook AP; Bergsland EK
Surg Oncol Clin N Am; 2007 Jul; 16(3):639-51, x. PubMed ID: 17606198
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.
Ho AS; Picus J; Darcy MD; Tan B; Gould JE; Pilgram TK; Brown DB
AJR Am J Roentgenol; 2007 May; 188(5):1201-7. PubMed ID: 17449759
[TBL] [Abstract][Full Text] [Related]
6. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors.
Ruszniewski P; O'Toole D
Neuroendocrinology; 2004; 80 Suppl 1():74-8. PubMed ID: 15477722
[TBL] [Abstract][Full Text] [Related]
7. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques.
Atwell TD; Charboneau JW; Que FG; Rubin J; Lewis BD; Nagorney DM; Callstrom MR; Farrell MA; Pitot HC; Hobday TJ
Cardiovasc Intervent Radiol; 2005; 28(4):409-21. PubMed ID: 16041556
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies for neuroendocrine liver metastases.
Frilling A; Clift AK
Cancer; 2015 Apr; 121(8):1172-86. PubMed ID: 25274401
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine liver metastases.
Reddy SK; Clary BM
Surg Clin North Am; 2010 Aug; 90(4):853-61. PubMed ID: 20637952
[TBL] [Abstract][Full Text] [Related]
10. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
Chen JX; Wileyto EP; Soulen MC
Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatic metastases of neuroendocrine malignancies: a 10-year experience.
Dejong CH; Parks RW; Currie E; Piris J; Redhead DN; Garden OJ
J R Coll Surg Edinb; 2002 Apr; 47(2):495-9. PubMed ID: 12018694
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic alternatives in metastatic neuroendocrine tumors.
Miller CA; Ellison EC
Surg Oncol Clin N Am; 1998 Oct; 7(4):863-79. PubMed ID: 9735138
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver.
Gaur SK; Friese JL; Sadow CA; Ayyagari R; Binkert CA; Schenker MP; Kulke M; Baum R
Cardiovasc Intervent Radiol; 2011 Jun; 34(3):566-72. PubMed ID: 21431978
[TBL] [Abstract][Full Text] [Related]
14. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
Christante D; Pommier S; Givi B; Pommier R
Surgery; 2008 Dec; 144(6):885-93; discussion 893-4. PubMed ID: 19040993
[TBL] [Abstract][Full Text] [Related]
15. Radiofrequency ablation of neuroendocrine hepatic metastasis.
Gamblin TC; Christians K; Pappas SG
Surg Oncol Clin N Am; 2011 Apr; 20(2):273-9, vii-viii. PubMed ID: 21377583
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study.
Fiorentini G; Rossi S; Bonechi F; Vaira M; De Simone M; Dentico P; Bernardeschi P; Cantore M; Guadagni S
J Chemother; 2004 Jun; 16(3):293-7. PubMed ID: 15330328
[TBL] [Abstract][Full Text] [Related]
17. Metastatic neuroendocrine hepatic tumors: resection improves survival.
Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
[TBL] [Abstract][Full Text] [Related]
18. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study.
Maire F; Lombard-Bohas C; O'Toole D; Vullierme MP; Rebours V; Couvelard A; Pelletier AL; Zappa M; Pilleul F; Hentic O; Hammel P; Ruszniewski P
Neuroendocrinology; 2012; 96(4):294-300. PubMed ID: 22507901
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of metastatic disease to the liver.
Arciero CA; Sigurdson ER
Semin Oncol; 2008 Apr; 35(2):147-59. PubMed ID: 18396200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
